Sionna Therapeutics, Inc.
For the period ended Mar 31, 2026. Filed May 12, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2026 · Filed May 12, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 5. Other Information
(a) None.
(b) None.
(c) The following table describes, for the three months ended March 31, 2026, each trading arrangement under which any of our directors or executive officers adopted, modified, orterminated any contract, instruction or written plan for the purchase or sale of our securities that was intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) or any "non-Rule 10b5-1 trading arrangements" as defined in Item 408(c) of Regulation S-K.
| Name (Title) | Action Taken (Date of Action) | Type of Trading Arrangement | Nature of Trading Arrangement | Expiration Date of Trading Arrangement (1) | Aggregate Number of Securities |
|---|---|---|---|---|---|
| Michael Cloonan (President and Chief Executive Officer) | Adoption (February 6, 2026) | Rule 10b5-1 trading arrangement | Sale | February 1, 2027 | Up to 325,000 shares |
| Elena Ridloff (Chief Financial Officer) | Adoption (February 6, 2026) | Rule 10b5-1 trading arrangement | Sale | May 1, 2027 | Up to 92,000 shares |
(1) A trading arrangement may expire on an earlier date if all contemplated transactions are completed before such trading arrangement's expiration date, upon termination by broker or the holder of the trading arrangement, or as otherwise provided in the trading arrangement.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.